Oral angioedema secondary to ACE inhibitors a frequently overlooked association: Case report and review

New Zealand Medical Journal

Volumn 119, Issue 1232, 2006, Pages

  Hurst, Miriam ^a   Empson, Marianne ^b  

^a LIVERPOOL HOSPITAL   (Australia)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PINDOLOL; STEROID; ANTIHYPERTENSIVE AGENT;

AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INTENSIVE CARE; MOUTH DISEASE; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CILAZAPRIL; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; MOUTH DISEASES; PINDOLOL; TREATMENT OUTCOME;

EID: 33645961611     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18:171-88.
2. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161:2417-29.
3. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599-606.
4. Pharmaceutical Management Agency. Annual review. Wellington: PHARMAC; 2004. Available online. URL: http://www.pharmac.govt.nz/pdf/ARev04.pdf Accessed April 2006.
5. Scott IA, Harper CM. Guideline-discordant care in acute myocardial infarction: predictors and outcomes. Med J Aus. 2002;177:26-31.
6. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-42.
7. Schmidt TD, McGrath, KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci. 2002;324:106-8.
8. Fuchs SA, Koopmans RP, Guchelaar HJ, et al. Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension. 2001;37:E1.
9. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
10. Jain M, Armstrong L, Hall J. Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy. Chest. 1992;102:871-4.
11. Agah R, Bandi V, Guntupalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med. 1997;23:793-6.
12. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997:278;232-233.
13. Weiner JM. Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy. Aus N Z J Med. 1995;25:241-2.
14. Slater EE, Merri DDI, Guess HA, et al. Clinical profile of angioedema associated with ACE inhibitors. JAMA. 1988; 260:967-70.
15. Cohen EG, Soliman AMS. Changing trends in angioedema. Ann Otol Rhinol Laryngol. 2001:8;701-6.
16. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci. 2001;46:1239-43.
17. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, et al. International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57:27-77.
18. Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39:460-4.
19. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088-9.
20. Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol. 1997;133:972-5.
21. Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol. 2002;109:370-1.
22. Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol. 2004;92:573-5.
23. Nielsen EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (Cl) inhibitor concentrate. Acta Anaesthesiol Scand. 2006:50;120-2.
24. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000;34:526-8.
25. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope. 2001:111;1729-31.
26. Cicardi M, Zingale L, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use. Arch Intern Med. 2004:164;910-3.
27. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of reninangiotensin system inhibition. Ann Intern Med. 2002;136:604-15.
28. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs. 2003;63:2185-202.
29. Nikpoor B, Duan QL, Rouleau GA. Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications. Expert Opin Pharmacother. 2005;6:1851-6.
30. Icatibant: HOE 140, JE 049, JE049. Drugs R D. 2004;5:343-8. Abstract available online. URL: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract& list uids=15563238&query_hl=2&itool=pubmed_docsum Accessed April 2006.
31. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci. 2003:29;255-8.